MeMed Secures Additional Funding From the Department of Defense

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

MeMed Ltd. reported that it has been awarded a $4,079,159 grant by the DoD’s Congressionally Directed Medical Research Programs (CDMRP). The award will support transition of the prototype point-of-care (POC) platform towards a final product, including transfer to manufacturing and implementation of cloud connectivity. The CDMRP grant complements a $9.2M contract from the Defense Threat Reduction Agency awarded last year to MeMed that is supporting the final stages of prototype development.

Kfir Oved, MD/PhD, MeMed’s CTO comments: “This grant will allow us to set up manufacturing processes for our POC platform, ultimately enabling MeMed’s novel blood test that has been clinically validated for differentiating between bacterial and viral infection to reach the patient in a shorter time.”

MeMed recently announced completion of a trilogy of clinical studies, two of which were double-blind, conducted over the past seven years, which collectively enrolled 2,376 patients*. The latest study, PATHFINDER, published in the official journal of the American Academy of Pediatrics, independently confirmed that MeMed’s novel blood test, accurately distinguishes between bacterial and viral infections in children. The test aims to support clinicians in one of the most routine yet challenging clinical dilemmas today – determining whether an infection is bacterial or viral in order to decide whether to treat or not to treat with antibiotics.

“Now that development is approaching completion, we are working to expand the menu of tests that will be available on the POC platform, including novel tests for predicting disease severity and for differentiating between sepsis and SIRS,” said Eran Eden, PhD, MeMed’s CEO. “Fast menu expansion is possible, as our unique platform paves the way to performing a wide range of other multiplex-protein measurements, with laboratory quality, within minutes at the POC – the basis for a panel of tests needed to advance patient care.”

*Oved et al. Plos One, 2015; van Houten et el. Lancet Infectious Diseases, 2016; Srugo et al. Pediatrics, 2017.

CDMRP grant information

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0694.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.